news
Ibuprofen better choice over oral morphine for pain relief in children
Widely available ibuprofen is a better choice for pain relief in children who have undergone minor surgery, as it has fewer adverse effects compared with oral morphine...
List view / Grid view
Drug toxicology studies
news
CBD may protect against psychiatric risk from high-THC cannabis strains
Neuroscientists have found that cannabidiol reduces symptoms such as impaired memory in adolescent mice simultaneously exposed to THC...
news
Study shows contrasting cognitive effects of psychiatric drugs
A long-term study has found that low cumulative exposure to benzodiazepine does not affect cognition in schizophrenia...
news
Combination of conventional drugs enhances tumour cell death
Brazilian researchers have investigated whether cisplatin and 5-FU would interfere with the protein pRB...
news
Sildenafil should be avoided in valvular disease
The SIOVAC trial2 has tested the potential of sildenafil to improve long-term outcomes of patients with residual pulmonary hypertension...
news
Cancer drug can reactivate HIV
A team of scientists have recently discovered how a new drug called JQ1 which is currently in early-phase human cancer trials, can reactivate latent HIV...
news
Compound derived from marijuana interacts with antiepileptic drugs
Cannabidiol is being studied as a potential anticonvulsant, and it has demonstrated effectiveness in animal models of epilepsy and in humans...
news
Study examines link between marijuana and vulnerability to psychosis
Going from an occasional user of marijuana to a weekly or daily user increases an adolescent’s risk of having recurrent psychotic-like experiences by 159%, according to a new Canadian study...
article
Integrating preclinical data into early clinical development
3 September 2012 | By Vikash Sinha, Clinical Pharmacology Leader, Janssen Research and Development
One of the important goals in preclinical and early clinical drug development is to reduce attrition rates and to improve our ability to pick winners and drop potential loser drug candidates. By being able to efficiently translate preclinical data and observations into possible clinical outcomes, one can make the drug…
article
The need for proteomic-based biomarkers in the drug development pipeline
10 July 2012 | By Paul C. Guest, Department of Chemical Engineering and Biotechnology, University of Cambridge and Sabine Bahn Department of Chemical Engineering and Biotechnology, University of Cambridge & Department of Neuroscience, Erasmus Medical Centre
Pharmaceutical companies are under increasing pressure to improve their efficiency and returns on drug discovery projects. This is a daunting task considering that the average drug costs approximately one billion US dollars to develop and takes around 12 years from initial discovery to reach the market1. In addition, approximately 70…
